Breakeven On The Horizon For Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480)

Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. On 31 December 2024, the HK$4.4b market-cap company posted a loss of CN¥168m for its most recent financial year. As path to profitability is the topic on Beijing Luzhu Biotechnology's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Consensus from 3 of the Hong Kong Biotechs analysts is that Beijing Luzhu Biotechnology is on the verge of breakeven. They anticipate the company to incur a final loss in 2026, before generating positive profits of CN¥90m in 2027. So, the company is predicted to breakeven approximately 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 59%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Beijing Luzhu Biotechnology's upcoming projects, though, keep in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for Beijing Luzhu Biotechnology

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 6.4% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Beijing Luzhu Biotechnology, so if you are interested in understanding the company at a deeper level, take a look at Beijing Luzhu Biotechnology's company page on Simply Wall St. We've also put together a list of pertinent aspects you should look at:

1. Valuation: What is Beijing Luzhu Biotechnology worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Beijing Luzhu Biotechnology is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Beijing Luzhu Biotechnology’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.